Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].

The journal of prevention of Alzheimer's disease·2025
Same author

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2025
Same author

Rapid identification of antibody impurities in size-based electrophoresis via CZE-MS generated spectral library.

Scientific reports·2024
Same author

Investigating SH-SY5Y Neuroblastoma Cell Surfaceome as a Model for Neuronal-Targeted Novel Therapeutic Modalities.

International journal of molecular sciences·2022
Same author

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species.

Journal of Alzheimer's disease reports·2022

Related Experiment Video

Updated: Jul 6, 2026

Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid
10:23

Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid

Published on: December 4, 2017

Proteomics of cerebrospinal fluid: methods for sample processing.

John E Hale1, Valentina Gelfanova, Jin-Sam You

  • 1Lilly Research Laboratories, Greenfield, Indiana, USA.

Methods in Molecular Biology (Clifton, N.J.)
|March 29, 2008
PubMed
Summary

Standardizing cerebrospinal fluid (CSF) sample processing is crucial for reliable proteomic analysis. This study details methods for CSF collection, storage, and processing to ensure reproducible biomarker discovery for brain disorders.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid for the Detection of Central Nervous System Pathogens
10:08

Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid for the Detection of Central Nervous System Pathogens

Published on: April 17, 2026

Related Experiment Videos

Last Updated: Jul 6, 2026

Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid
10:23

Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid

Published on: December 4, 2017

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid for the Detection of Central Nervous System Pathogens
10:08

Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid for the Detection of Central Nervous System Pathogens

Published on: April 17, 2026

Area of Science:

  • Neuroscience
  • Biochemistry
  • Proteomics

Background:

  • Cerebrospinal fluid (CSF) is a vital source for identifying biomarkers of neurological disorders and aiding drug development.
  • Proteomic analysis of CSF is increasingly utilized for understanding brain conditions.
  • Reproducibility in CSF proteomic studies depends heavily on standardized pre-analytical and analytical procedures.

Purpose of the Study:

  • To present standardized methodologies for cerebrospinal fluid (CSF) sample processing.
  • To facilitate reliable protein identification and quantification in CSF for biomarker discovery.
  • To support the advancement of proteomic applications in neurological research and therapeutic development.

Main Methods:

  • Detailed protocols for CSF sample collection and storage.
  • Standardized procedures for sample preparation tailored to various proteomic techniques.
  • Guidelines for consistent downstream processing to minimize variability.

Main Results:

  • Established a comprehensive workflow for CSF sample processing.
  • Demonstrated the importance of standardization for reproducible proteomic data.
  • Provided a foundation for robust biomarker identification in CSF.

Conclusions:

  • Standardized CSF sample processing is essential for accurate and reproducible proteomic biomarker discovery.
  • The described methods enhance the reliability of CSF analysis for brain disorder research.
  • Implementation of these protocols will advance therapeutic drug development through improved biomarker identification.